Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
Complement 3 glomerulopathy (C3 glomerulopathy) is a very rare kidney disease. Those diagnosed with it have one of two forms of this disease: dense deposit disease (DDD) or C3 glomerulonephritis (C3GN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback